Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer

Anouk K.M. Claessens; Jan J.V. Busschbach; on behalf of the Dutch Breast Cancer Research Group (BOOG); Bram L.T. Ramaekers; Frans L.G. Erdkamp; Jeanette M. Bouma; A. Elise van Leeuwen-Stok; Vivianne C.G. Tjan-Heijnen; Monique E.M.M. Bos

doi:10.1080/0284186X.2022.2033832

Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer

Anouk K.M. Claessens, Jan J.V. Busschbach, on behalf of the Dutch Breast Cancer Research Group (BOOG), Bram L.T. Ramaekers, Frans L.G. Erdkamp, Jeanette M. Bouma, A. Elise van Leeuwen-Stok, Vivianne C.G. Tjan-Heijnen, Monique E.M.M. Bos^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

11 Downloads (Pure)

Original language	English
Pages (from-to)	619-624
Number of pages	6
Journal	Acta Oncologica
Volume	61
Issue number	5
DOIs	https://doi.org/10.1080/0284186X.2022.2033832
Publication status	Published - 9 Feb 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/0284186X.2022.2033832Licence: Unspecified

Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancerFinal published version, 1.33 MBLicence: Unspecified

Cite this

Claessens, A. K. M., Busschbach, J. J. V., on behalf of the Dutch Breast Cancer Research Group (BOOG), Ramaekers, B. L. T., Erdkamp, F. L. G., Bouma, J. M., van Leeuwen-Stok, A. E., Tjan-Heijnen, V. C. G., & Bos, M. E. M. M. (2022). Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer. Acta Oncologica, 61(5), 619-624. https://doi.org/10.1080/0284186X.2022.2033832

@article{8fa3b68210e8439db2ce740cc0e8c694,

title = "Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer",

author = "Claessens, {Anouk K.M.} and Busschbach, {Jan J.V.} and {on behalf of the Dutch Breast Cancer Research Group (BOOG)} and Ramaekers, {Bram L.T.} and Erdkamp, {Frans L.G.} and Bouma, {Jeanette M.} and {van Leeuwen-Stok}, {A. Elise} and Tjan-Heijnen, {Vivianne C.G.} and Bos, {Monique E.M.M.}",

year = "2022",

month = feb,

day = "9",

doi = "10.1080/0284186X.2022.2033832",

language = "English",

volume = "61",

pages = "619--624",

journal = "Acta Oncologica",

issn = "0284-186X",

publisher = "Medical Journals Sweden AB",

number = "5",

}

Claessens, AKM, Busschbach, JJV, on behalf of the Dutch Breast Cancer Research Group (BOOG), Ramaekers, BLT, Erdkamp, FLG, Bouma, JM, van Leeuwen-Stok, AE, Tjan-Heijnen, VCG & Bos, MEMM 2022, 'Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer', Acta Oncologica, vol. 61, no. 5, pp. 619-624. https://doi.org/10.1080/0284186X.2022.2033832

Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer. / Claessens, Anouk K.M.; Busschbach, Jan J.V.; on behalf of the Dutch Breast Cancer Research Group (BOOG) et al.
In: Acta Oncologica, Vol. 61, No. 5, 09.02.2022, p. 619-624.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer

AU - Claessens, Anouk K.M.

AU - Busschbach, Jan J.V.

AU - on behalf of the Dutch Breast Cancer Research Group (BOOG)

AU - Ramaekers, Bram L.T.

AU - Erdkamp, Frans L.G.

AU - Bouma, Jeanette M.

AU - van Leeuwen-Stok, A. Elise

AU - Tjan-Heijnen, Vivianne C.G.

AU - Bos, Monique E.M.M.

PY - 2022/2/9

Y1 - 2022/2/9

UR - http://www.scopus.com/inward/record.url?scp=85125308924&partnerID=8YFLogxK

U2 - 10.1080/0284186X.2022.2033832

DO - 10.1080/0284186X.2022.2033832

M3 - Article

C2 - 35139727

AN - SCOPUS:85125308924

SN - 0284-186X

VL - 61

SP - 619

EP - 624

JO - Acta Oncologica

JF - Acta Oncologica

IS - 5

ER -

Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer

UN SDGs

Access to Document

Other files and links

Cite this